Physician profile
Michael A Sherer
NPI 1558378067
$1,140.05
in general payments reported to CMS, 2019-2025
11 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Neurodevelopmental Disabilities (Psychiatry & Neurology) provider received nationally (typical 2025 total: $328).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $44.06 · 2022: $215 · 2024: $207 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.85 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $180.77 | 2019-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $156.80 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $138.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $121.05 | 2022-2024 | Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $65.00 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $62.20 | 2020-2025 | Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $61.40 | 2019 | |
| Abbvie INC. | $45.22 | 2024 | |
| Acadia Pharmaceuticals INC | $30.31 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.99 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.